NCT02542124View on ClinicalTrials.gov

NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)

PHASE2UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

February 28, 2019

Study Completion Date

May 31, 2019

Conditions
Cutaneous T Cell Lymphoma (CTCL)Mycosis FungoidesSézary Syndrome
Interventions
BIOLOGICAL

NM-IL-12 and TSEBT

The LD-TSEBT treatment will start on Day 1 of the study. NM-IL-12 will be administered subcutaneously.

Trial Locations (3)

10032

Columbia University Medical Center, New York

19104

University of Pennsylvania, Philadelphia

94305

Stanford Cancer Center, Stanford

Sponsors

Lead Sponsor

Neumedicines Inc.
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Neumedicines Inc.

INDUSTRY

NCT02542124 - NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) | Biotech Hunter | Biotech Hunter